Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

BMY 57.04 +1.81 (3.28%)
price chart
Bristol-Myers to buy Amylin for about $5.3 billion
NEW YORK Bristol-Myers Squibb Co will buy biotechnology company Amylin Pharmaceuticals Inc for about $5.3 billion in cash, helping Bristol-Myers extend its portfolio of diabetes treatments with the addition of drugs Byetta and Bydureon.
Bristol-Myers in Deal for Amylin Valued at $7 Billion  New York Times (blog)
Bristol-Myers outbids Big Pharma pack and nabs Amylin for $5.3B  FierceBiotech
BBDO, CDM Said to Win Big Bristol-Myers Squibb Brand
Omnicom agencies BBDO New York and The CDM Group have been given U.S. creative lead responsibilities for Bristol-Myers Squibb's Abilify antidepressant drug, sources said. The brand, which had been at Digitas Health, spent $133.7 million in U.S. ...
Bristol-Myers Squibb - Abilify
And finally... There is Bristol-Myers ($BMY) and its bad behavior. Its 2007 settlement covered a number of violations, such as gaming the system to jack up prices on Serzone.
Dying man fights to get experimental drug from Bristol-Myers Squibb
Darcy Doherty, 48, is dying of cancer and believes his last chance at life is an experimental drug that a pharmaceutical company refuses to give him. Doherty, shown with wife Rebecca at their Toronto home, is battling to get the firm to change its mind.
FDA Once Again Delays Approval Of Apixaban (Eliquis)
PRINCETON, N.J. & NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced that the U.S.
Bristol-Myers Hits Sandoz Over Generic Hepatitis Drug
Law360, New York (June 21, 2012, 7:39 PM EDT) -- Bristol-Myers Squibb Co. on Thursday filed suit in Delaware federal court alleging Sandoz Inc.'s plan to make a generic version of the hepatitis B drug Baraclude would lead to infringement of BMS' patent ...
Insight: Top heart doctors fret over new blood thinners
"Research has shown that the number of reported adverse events for a drug peaks during its first few years on the market," when doctors are most likely to file voluntary reports to regulators and drugmakers, company spokeswoman Emily Baier said.
Top heart doctors fret over new blood thinners  Fox News
Docs fret over new blood thinners  Free Malaysia Today
AstraZeneca $4bn approach for diabetes specialist Amylin
For Astra, which on Sunday declined to comment, the purchase would enable it to replace sales lost on existing drugs when patent protection expires.
Six-Year Follow-Up Data for SPRYCEL� (dasatinib) 100 mg Once Daily ...
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL� (dasatinib) in Philadelphia ...
New CEO at high-flying Mead Johnson catches a company at its peak
The Denmark native and 14-year company veteran is taking over a Glenview-based business whose net sales have climbed 30 percent, to $3.7 billion, since 2009, when it was spun off from Bristol-Myers Squibb Co. Mr. Jakobsen, 50, was named chief ...